CAS 934828-12-3

HDAC-IN-4

CAS : 934828-12-3

Formule : C₂₄H₂₉N₅O

Degré de pureté : 99%

Masse moléculaire : 403.52

Ref: IN-DA00GUB5

N-(2-Aminophenyl)-4-(1-((1,3-Dimethyl-1H-Pyrazol-4-Yl)Methyl)Piperidin-4-Yl)Benzamide

CAS : 934828-12-3

N-(2-Aminophenyl)-4-(1-((1,3-Dimethyl-1H-Pyrazol-4-Yl)Methyl)Piperidin-4-Yl)Benzamide

Degré de pureté : 99%

Masse moléculaire : 403.52g/mol

Ref: 54-OR1024284

CXD101

CAS : 934828-12-3

CXD101

Degré de pureté : ≥95%

Masse moléculaire : 403.52g/mol

Ref: 54-BUP04793

CXD101

CAS : 934828-12-3

CXD101 is a novel class I-selective HDACi (HDAC1 (IC50 : 63nM), HDAC2 (IC50 :570nM), HDAC3 (IC50 :550nM)). CXD101(CXD-101) has no activity against HDAC class II

Formule : C₂₄H₂₉N₅O

Degré de pureté : 99.82%

Couleur et forme : Solid

Masse moléculaire : 403.52

Ref: TM-T5347

CXD101

CAS : 934828-12-3

CXD101 is a small molecule inhibitor of histone deacetylase (HDAC) enzymes. It is a potent, selective, and reversible inhibitor of HDACs 1, 2, and 3. CXD101 has been shown to induce cell death in solid tumours through the inhibition of HDACs. In vitro studies have shown that it inhibits the growth of cancer cells by inducing apoptosis and inhibiting the transcriptional activity of Hdac enzymes on histones. These findings indicate that CXD101 may be useful for the treatment of cancers. CXD101 has been well tolerated in clinical trials with no significant adverse effects reported.
CXD101 is an amide-linked prodrug which undergoes rapid acetylation by esterases in vivo to form its active metabolite, cixutumumab (CX1001). Acetylation occurs mainly in the liver, followed by rapid elimination from plasma with a half-life of

Formule : C₂₄H₂₉N₅O

Degré de pureté : Min. 95%

Masse moléculaire : 403.52 g/mol

Ref: 3D-JMB82812